ArticleHematology. American Society of Hematology. Education Program2021
Allogeneic hematopoietic cell transplantation for older patients.
Article in Hematology. American Society of Hematology. Education Program, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Decitabine induces cell differentiation and growth inhibition accompanied by upregulation of microRNA-143 and MS4A3 in the myelodysplastic syndromes-derived leukemic cell line MDS-L.Oncology letters · 2026Article
- Significance of CD34Transplantation and cellular therapy · 2026Article
- Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.Blood advances · 2026Article
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.Transplantation and cellular therapy · 2025Review
- Article
- Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups.Cancers · 2025Review
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.Yonago acta medica · 2025Review
- Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy.European journal of haematology · 2025Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).Current oncology (Toronto, Ont.) · 2025Review
- Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.Bone marrow transplantation · 2025Article
- Article
- Venous Thromboembolism Prophylaxis after Hematopoietic Cell Transplantation: Still a Challenge for Hematologists and Hemostasiologists.Thrombosis and haemostasis · 2025Article
- Access to Transplant Care and Social Determinants of Health.Advances in experimental medicine and biology · 2025Review
- Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.Advances in experimental medicine and biology · 2025Review
- The Anti-Leukemic Potential of Bee Venom.International journal of general medicine · 2025Review
- Review
- Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML.Research square · 2024Article
- Review
- Transplantation and Cellular Therapy for Older Adults-The MSK Approach.Current hematologic malignancy reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hematologic malignances are more common and often higher risk in older patients. Allogeneic hematopoietic cell transplantation (alloHCT) best enables long-term disease control for patients with poor risk or relapsed/refractory hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, or myelofibrosis. Rates of alloHCT among older patients, while still relatively low compared with younger patients, have risen sharply over the past decade. Accumulating evidence supports alloHCT for patients ≥60 years of age relative to non-HCT therapies based on improved overall and disease-free survival. However, a significant proportion of older adults have limitations characterized by geriatric assessment. A systematic process to evaluate and optimize older patients may improve decision making, transplant outcomes, and alloHCT access. We present case-based studies to illustrate a stepwise and rational approach to proper older patient evaluation, pretransplant optimization, and posttransplant care with attention to important geriatric issues and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.